Part 11/13:
Long-term research initiatives aim to deepen understanding of menopause’s effects and develop better treatments. For example, France is conducting a decade-long study involving 100,000 women, tracking their menopausal experiences to inform future healthcare strategies. Meanwhile, pharmaceutical companies are rolling out new non-hormonal therapies, such as treatments approved in Canada and the UK, which promise relief without hormone-related risks.
Yet, bureaucratic and regulatory delays hinder timely access to these innovations. Campaigners warn that unless governments and industries prioritize women's health, countless women will continue to suffer unnecessarily, losing valuable years of their lives and careers.